- Home
- AVNT vs RARE Comparison
AVNT vs RARE Comparison
Compare AVNT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNT | RARE |
|---|---|---|
| Founded | 1927 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.1B |
| IPO Year | 2000 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AVNT | RARE |
|---|---|---|
| Price | $32.99 | $20.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | $41.50 | ★ $64.05 |
| AVG Volume (30 Days) | 630.3K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | ★ 7.31 |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $3,835,500,000.00 | $673,000,000.00 |
| Revenue This Year | $4.81 | $13.40 |
| Revenue Next Year | $3.37 | $42.83 |
| P/E Ratio | $37.07 | ★ N/A |
| Revenue Growth | 1.71 | ★ 20.13 |
| 52 Week Low | $27.48 | $18.41 |
| 52 Week High | $44.85 | $40.21 |
Technical Indicators
Market Signals| Indicator | AVNT | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 21.75 | 36.66 |
| Support Level | $32.13 | $19.61 |
| Resistance Level | $33.15 | $23.44 |
| Average True Range (ATR) | 1.18 | 0.80 |
| MACD | -0.81 | -0.03 |
| Stochastic Oscillator | 0.96 | 1.96 |
Price Performance
Historical ComparisonAbout AVNT Avient Corporation
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.